Literature DB >> 27634031

Prognostic Significance of Nonsustained Ventricular Tachycardia Episodes Occurring Early After Implantable Cardioverter-Defibrillator Implantation Among Patients With Left Ventricular Dysfunction.

Javier Jiménez-Candil1, Jesús Hernández2, Pedro Perdiguero2, Ana Martín2, José Moríñigo2, Loreto Bravo2, Olga Durán2, Pedro Luis Sánchez2.   

Abstract

Nonsustained ventricular tachycardias (NSVTs) are frequently observed in patients with left ventricular (LV) dysfunction. The prognostic implications of such NSVTs are conflicting. Our objective was to determine the relation between the burden of NSVT occurring early (within the first 6 months after ICD implant) and prognosis among ICD patients with LV dysfunction. We followed 416 ICD patients (age: 65 ± 11 years; LV ejection fraction: 30 ± 8; ischemic origin: 62%; primary prevention: 63%) with LV dysfunction for 41 ± 27 months. ICD programming was standardized. NSVT was defined as any VT of ≥5 beats at ≥150 beats/min which did not meet the detection criteria occurring within the first 6 months after ICD implant. A total of 250 patients (60%) presented at least one NSVT (median = 2; interquartile range 0 to 7). We classified the patients into 3 groups according to the number of NSVTs: no NSVT (n = 166); 1 to 5 NSVTs (n = 130); and >5 NSVTs (n = 120). The incidence of cardiac mortality (7.2% vs 17.7% vs 31.7%; p = 0.003), hospitalizations for heart failure (10.6% vs 24.4% vs 44.7%; p <0.001), and appropriate shock (15.7% vs 24.8% vs 43.8%; p <0.001) increased significantly with the number of NSVTs. By multivariate analysis, >5 NSVTs were found to be an independent predictor of cardiac mortality (hazard ratio [HR] 1.75; p = 0.03), hospitalization due to heart failure (HR 1.72; p = 0.001), and appropriate shock (HR 1.89; p <0.001) but not of inappropriate therapy (HR 0.9; p = 0.6). In conclusion, among ICD patients with LV dysfunction, NSVT episodes occurring in the first 6 months after implant are independently associated with a poor prognosis. Subjects with >5 NSVTs are at the highest risk.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27634031     DOI: 10.1016/j.amjcard.2016.08.015

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Prognostic relevance of new onset arrhythmia and ICD shocks in primary prophylactic ICD patients.

Authors:  Thomas Kleemann; Margit Strauss; Kleopatra Kouraki; Nicolas Werner; Ralf Zahn
Journal:  Clin Res Cardiol       Date:  2019-05-13       Impact factor: 5.460

2.  Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy.

Authors:  Arwa Younis; Mehmet K Aktas; Wojciech Zareba; Scott McNitt; Valentina Kutyifa; Ilan Goldenberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-03-27       Impact factor: 1.468

3.  Clinical and Echocardiographic Predictors of Arrhythmias Detected With 24-Hour Holter Electrocardiography Among Hypertensive Heart Failure Patients in Nigeria.

Authors:  Tuoyo Omasan Mene-Afejuku; Michael Olabode Balogun; Anthony Olubunmi Akintomide; Rasaaq Ayodele Adebayo; Olufemi Eyitayo Ajayi; Valentine N Amadi; Omolola Abiodun Oketona; Amanze Nkemjika Ikwu; Bamidele Mene-Afejuku; Olaniyi James Bamikole
Journal:  Clin Med Insights Cardiol       Date:  2017-12-10

4.  Prognostic role of non-sustained ventricular tachycardia detected with remote interrogation in a pacemaker population.

Authors:  Stefano Poli; Domenico Facchin; Francesca Rizzetto; Luca Rebellato; Elisabetta Daleffe; Mauro Toniolo; Antonella Miconi; Alessandro Altinier; Corrado Lanera; Stefano Indrigo; Jennifer Comisso; Alessandro Proclemer
Journal:  Int J Cardiol Heart Vasc       Date:  2019-01-08

5.  Cycle length of nonsustanied ventricular tachycardias among ICD patients: implications on subsequent appropriate therapies.

Authors:  Javier Jiménez-Candil; Olga Duran; Armando Oterino; Jendri Pérez; Juan Carlos Castro; Jesús Hernández; José Moríñigo; Manuel Sánchez García; Pedro L Sánchez
Journal:  BMC Cardiovasc Disord       Date:  2021-05-31       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.